



21st Century Therapeutics, Inc.

1366 Hilton Road
Ferndale, MI 48220

For Immediate Release

August 31, 2011

Pharmaceutical Research Firm Receives a \$1.1 million Grant from NIH

Ferndale based 21st Century Therapeutics, Inc. (21CTI) received a two-year research grant of \$1.1 million from National Institutes of Health (NIH) to study a small-molecule Tumor Necrosis Factor- α (TNF- α) inhibitor as a chemoprotector to reduce cisplatin-induced side effects. According to 21CTI's CEO, Dr. Frederick Valeriote, this is the third SBIR grants received by 21CTI.

"This research grant will help us further the preclinical development of UTL-5g as a chemoprotector", said Valeriote. This 2-year Phase II grant is a continuation of a Phase I grant under the Small Business Innovative Research (SBIR) program sponsored by the NIH.

According to 21CTI's president and the Principal Investigator of this study, Dr. JJ Shaw, cisplatin is a widely prescribed anticancer drug with side effects including nephrotoxicity (kidney damage), hepatotoxicity (liver damage) and hematotoxicity (toxicity in blood cells). Based on the recently completed Phase I study, pretreatment of UTL-5g reduced nephrotoxicity and hepatotoxicity induced by cisplatin, and increased blood platelet counts in mice. Furthermore, pretreatment of UTL-5g increased the therapeutic efficacy of cisplatin against HCT-15 human colon cancer cells inoculated in mice. The successful Phase I study resulted a patent application filed in the US Patent and Trademark Office (PTO), and a scientific paper published in Journal of Experimental Therapeutics and Oncology (2011, volume 9 p. 129-137). Based on these promising results, 21CTI plans to use this newly awarded Phase II funding to continue the preclinical development of UTL-5g during the next two years.

21CTI is a private pharmaceutical discovery and development company, specializing in cancer and immune-mediated diseases. In addition to UTL-5g, several other anticancer agents and immune modulators are in preclinical development.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchanges rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. 21CTI's management does not undertake any responsibility to update the forward-looking statements contained in this release.

Contact: Frederick Valeriote (586) 863-8298 or JJ Shaw (734) 330-6052

Website: www.21-cti.com

e-mail: jshaw@21-cti.com or jjajushaw@gmail.com